TGFBR2 and colorectal carcinoma: Because we were interested in ultimately studying metastatic CRC, we then knocked out Tgfbr2, which has reduced expression in BRAF mutant CRC as compared to normal colon and BRAF wildtype CRC, and Trp53 in the organoids using a CRISPR/Cas9 approach (Fig. S1L, S1M).